Table 2.

Association of androgen receptor expression with clinicopathologic features of endometrial carcinoma

	n (%)					P value
	Negative (n = 71)	Low (n = 7)	Moderate (n = 10)	High (n = 1)	Total (n = 89)
Menopausal status
Pre menopausal	14 (19.7)	2 (28.6)	1 (10)	0 (0)	17 (19.1)	0.743
Post menopausal	57 (80.3)	5 (71.4)	9 (90)	1 (100)	72 (80.9)
Histological type
Endometrioid	62 (87.3)	5 (71.4)	10 (100)	0 (0)	77 (86.5)	0.117
Serous	4 (5.6)	2 (28.6)	0 (0)	1 (100)	7 (7.9)
Clear cell	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (1.1)
Carcinosarcoma	4 (5.6)	0 (0)	0 (0)	0 (0)	4 (4.5)
Grade
Grade I	28 (39.4)	3 (42.9)	4 (40)	0 (0)	35 (39.3)	0.293
Grade II	30 (42.3)	2 (28.6)	6 (60)	0 (0)	38 (42.7)
Grade III	13 (18.3)	2 (28.6)	0 (0)	1 (100)	16 (18)
Myometrial invasion
Limited to endometrium	4 (5.6)	0 (0)	2 (20)	0 (0)	6 (6.7)	0.518
< 1/2 of myometrium	26 (36.6)	3 (42.9)	2 (20)	0 (0)	31 (34.8)
> 1/2 of myometrium	41 (57.7)	4 (57.1)	6 (60)	1 (100)	52 (58.4)
Cervical invasion
Present	17 (23.9)	3 (42.9)	3 (30)	0 (0)	23 (25.8)	0.581
Absent	54 (76.1)	4 (57.1)	7 (70)	1 (100)	66 (74.2)
Nodal status
N0	67 (94.4)	6 (85.7)	10 (100)	1 (100)	84 (94.4)	0.499
N1	3 (4.2)	1 (14.3)	0 (0)	0 (0)	4 (4.5)
N2	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (1.1)
Lymphovascular invasion
Present	5 (7)	1 (14.3)	0 (0)	0 (0)	6 (6.7)	0.529
Absent	66 (93)	6 (85.7)	10 (100)	1 (100)	83 (93.3)
T stage
T1	51 (71.8)	4 (57.1)	6 (60)	1 (100)	62 (69.7)	0.607
T2	10 (14.1)	3 (42.9)	3 (30)	0 (0)	16 (18)
T3	7 (9.9)	0 (0)	1 (10)	0 (0)	8 (9)
T4	3 (4.2)	0 (0)	0 (0)	0 (0)	3 (3.4)
FIGO stage
Stage IA	28 (39.4)	2 (28.6)	4 (40)	0 (0)	34 (38.2)	0.853
Stage IB	22 (31)	2 (28.6)	2 (20)	1 (100)	27 (30.2)
Stage II	11 (15.5)	3 (42.9)	3 (30)	0 (0)	17 (19.1)
Stage IIIA	6 (8.5)	0 (0)	1 (10)	0 (0)	7 (7.9)
Stage IIIB	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (1.1)
Stage IV	3 (4.2)	0 (0)	0 (0)	0 (0)	3 (3.4)

Fisher exact test applied

P value ≤ 0.05, considered as significant